🔎 Trials Near Me

Početna › Folikularni limfom › Texas

Kliničke studije za Folikularni limfom u državi Texas

35 studija za Folikularni limfom traži sudionike na lokacijama u državi Texas.

Gradovi u državi Texas

Službeni tekst studije (engleski)

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

  • NEXT Dallas, Irving
  • NEXT Oncology, San Antonio
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT03460977

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Texas Children's Hospital, Houston
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  • Research Site, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT06542250

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Md Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05006716

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Texas Oncology - DFW (Sammons CC), Dallas
  • Baylor College of Medicine, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • University of Texas Southwestern, Dallas
  • MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07101328

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

  • Baylor Scott & White Research Institute, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics (START), San Antonio
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT05765812

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  • Research Site, Austin
  • Research Site, Lubbock
  • Research Site, Shenandoah
  • i još 1
U tijeku regrutacijaFaza 3
Od 18 do 130 godina · Oba spola · Ažurirano 21. ruj 2026. · NCT06549595

NEO100 and High-Grade Meningioma

  • Baylor Scott and White, Dallas
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT05023018

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  • Research Site, Austin
  • Research Site, Houston
  • Research Site, San Antonio
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06526793

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  • Texas Oncology, Dallas
U tijeku regrutacijaFaza 3
Od 12 do 100 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT06784752

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  • Center for Oncology and Blood Disorders, Houston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06091254

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

  • MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT06043323

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

  • Research Site, San Antonio
U tijeku regrutacijaFaza 1Zdravi dobrovoljci dobrodošli
Od 18 do 85 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT07546760

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

  • M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 31. kol 2026. · NCT06108232

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • University of Texas Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
  • University of Texas Health Mays Cancer Center, San Antonio
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT05303519

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Baylor University Medical Center, Dallas
  • Texas Transplant Institute, San Antonio
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579

Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

  • Natera, Inc., Austin
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT07750886

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

  • The University of TX MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. srp 2026. · NCT07424833

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

  • Memorial Hermann Hospital / UTHealth McGovern Medical School at Houston, Houston
  • The University of Texas Health Science at San Antonio, San Antonio
U tijeku regrutacijaFaza 2
Od 18 do 55 godina · Oba spola · Ažurirano 15. srp 2026. · NCT05951777

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

  • Texas Liver Institute - American Research Corporation, San Antonio
  • Pinnacle Clinical Research, San Antonio
U tijeku regrutacijaFaza 1
Od 18 do 80 godina · Oba spola · Ažurirano 16. lip 2026. · NCT07559474

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  • Texas Oncology - Central/South Texas, Austin
  • Local Institution - 0212, Fort Worth
  • Local Institution - 0230, San Antonio
  • i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 20. svi 2026. · NCT06911502

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • University of Texas(UT) Southwestern-Children's Medical Center, Dallas
U tijeku regrutacijaFaza 1/2
Od 12 do 95 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. ožu 2026. · NCT04830137

Study of SGR-1505 in Mature B-Cell Neoplasms

  • University of Texas Southwestern, Dallas
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT05544019

Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery

  • University of Texas Medical Branch at Galveston, TX, Galveston
U tijeku regrutacija
Od 50 godina i više · Žene · Ažurirano 11. velj 2026. · NCT07206121

Cognitive Screening Made Easy for PCPs - Administrative Supplement

  • Family Wellness Clinic, Austin
  • University of Texas Health Austin Primary Care Clinic, Austin
  • UT Health San Antonio's Geriatrics and Supportive Care Clinic, San Antonio
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 60 godina i više · Oba spola · Ažurirano 5. velj 2026. · NCT06928298

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • Oncology Consultants, Houston
  • University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. pro 2025. · NCT05602363

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

  • SCRI, San Antonio
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. stu 2025. · NCT05643742

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Dallas
  • Massive Bio SYNERGY-AI site, Houston
  • Massive Bio SYNERGY-AI site, Temple
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University of Texas Southwestern Medical Center, Dallas
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2025. · NCT05780034

Phosphatidylethanol and Other Ethanol Consumption Markers

  • University of North Texas, Denton
  • University of Texas Health Science Center San Antonio, San Antonio
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 21 godina i više · Oba spola · Ažurirano 13. svi 2025. · NCT06747364

Paper-Based and Smartphone-Based Memory Supports

  • UT Health Austin Comprehensive Memory Center, Austin
  • Baylor Scott & White Healthcare, Temple
  • Baylor University, Waco
U tijeku regrutacija
Od 50 godina i više · Oba spola · Ažurirano 9. srp 2024. · NCT06444841

Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.